![40 pounds [24 kg] in 48 weeks ] Lilly’s new drug also reduces the desire for candy and alcohol](/_next/image?url=https%3A%2F%2Fsinjali.com%2Fwp-content%2Fuploads%2F2026%2F11%2Filaci_i_ri_i_lillyt_24_kilograme_me_pak_ne_nje_vit_dhe_me_pa_cbf349ba55.webp&w=3840&q=60)
The American pharmaceutical company Eli Lilly has presented promising results from a new combination of two anti – obesity drugs, which in a study has helped patients to lose up to 23.3 percent of their body weight in 48 weeks.
The combination, called Elora T ZP, includes tyrzepatide, the active substance of the Zepbound drug, and eloralintide, an experimental medicine that operates on hormonal mechanisms of saturation.
According to data presented by the company at the ObbetyWeek conference in Washington, obesity and Type 2 patients lost up to 23.3 percent of their weight after 48 weeks of treatment. For a person who has an initial weight of 105 pounds [ 105 kg], this is translated into about 245 pounds [24.5 kg] less.
The results include improvements in health indicators. Up to 60 percent of the participants failed to meet their obesity criteria, while up to 77 percent reached normal blood sugar levels.
Another aspect of study relates to a change in relationship with food. Some 74 percent of patients who received eloalinthide reported less desire to eat, especially for dessert. Additionally, 41 percent of those who consumed alcohol said that they had reduced its amount, while half reported a steady diet of food known as food cooking.
Lilly also presented data on the reform, another experimental drug that operates on three hormonal objectives. In patients with obesity and sleep appensities, treatment reduced respiratory shortages at night to 60.6 percent. While knee – arrhesives were reported as a loss of pain by about 75 percent.
The company also brought information on the use of Zepbound in teenagers aged 12 to 18. After 72 weeks, the body mass index dropped by 21.4 percent, and more than half of the participants no longer met obesity criteria.
However, the results of Elora TZP and reform are still in the study phase and these drugs are not approved for use. The data was presented by the company itself and has not yet been published in a scientific magazine. The side effects of this family of medications, including nausea, diarrhea, and vomiting, remain an important concern.
The signal where the truth speaks before the news!
Source Layer: Signal
